Open Orphan Coronavirus and RSV human challenge studies underway (Interviews)

Open Orphan plc (LON:ORPH) in a string of positive news releases catch up with DirectorsTalk to discuss two human study challenges.

Executive Chairman Cathal Friel joins DirectorsTalk to discuss the commencement of development of world’s first commercial human coronavirus challenge study model. Cathal provides us with more details on the study, explains how this will be funded and the timelines expected for the study.

Cathal also joins DirectorsTalk to discuss the signing of a new contract with a European Biotech Company for the provision of a RSV human challenge study. Cathal explains what the study entails, what it means for the company, the timescales involved and what else is going on in the company.

You might also enjoy reading  Open Orphan signs £5.7m human challenge study contract
Find more news, interviews, share price & company profile here for:
Open Orphan plc

Share this interview

Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on facebook
Facebook
Share on email
Email
Share on whatsapp
WhatsApp
Covid 19 Study
Open Orphan Coronavirus and RSV human challenge studies underway (Interviews)

Other Interviews

More News

Ask your questions

Do you have questions you’d like to ask this company, get in touch and we’ll ask them for you.   

I have questions